116 related articles for article (PubMed ID: 32115152)
1. Organ-specific regulation of CHD1 by acute PTEN and p53 loss in mice.
Rahmy S; Cheng X; Wang M; Feng H; Qiu W; Zhao R; Lu X
Biochem Biophys Res Commun; 2020 May; 525(3):614-619. PubMed ID: 32115152
[TBL] [Abstract][Full Text] [Related]
2. Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer.
Zhao D; Cai L; Lu X; Liang X; Li J; Chen P; Ittmann M; Shang X; Jiang S; Li H; Meng C; Flores I; Song JH; Horner JW; Lan Z; Wu CJ; Li J; Chang Q; Chen KC; Wang G; Deng P; Spring DJ; Wang YA; DePinho RA
Cancer Discov; 2020 Sep; 10(9):1374-1387. PubMed ID: 32385075
[TBL] [Abstract][Full Text] [Related]
3. Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer.
Zhao D; Lu X; Wang G; Lan Z; Liao W; Li J; Liang X; Chen JR; Shah S; Shang X; Tang M; Deng P; Dey P; Chakravarti D; Chen P; Spring DJ; Navone NM; Troncoso P; Zhang J; Wang YA; DePinho RA
Nature; 2017 Feb; 542(7642):484-488. PubMed ID: 28166537
[TBL] [Abstract][Full Text] [Related]
4. Common Genomic Aberrations in Mouse and Human Breast Cancers with Concurrent P53 Deficiency and Activated PTEN-PI3K-AKT Pathway.
Martinez JD; Mo Q; Xu Y; Qin L; Li Y; Xu J
Int J Biol Sci; 2022; 18(1):229-241. PubMed ID: 34975329
[TBL] [Abstract][Full Text] [Related]
5. SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence.
Hernández-Llodrà S; Segalés L; Juanpere N; Marta Lorenzo T; Salido M; Nonell L; David López T; Rodríguez-Vida A; Bellmunt J; Fumadó L; Cecchini L; Lloreta-Trull J
Prostate; 2021 Dec; 81(16):1267-1277. PubMed ID: 34533858
[TBL] [Abstract][Full Text] [Related]
6. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.
Li N; Xue W; Yuan H; Dong B; Ding Y; Liu Y; Jiang M; Kan S; Sun T; Ren J; Pan Q; Li X; Zhang P; Hu G; Wang Y; Wang X; Li Q; Qin J
J Clin Invest; 2017 Apr; 127(4):1284-1302. PubMed ID: 28319045
[TBL] [Abstract][Full Text] [Related]
7. MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2.
Nowak DG; Cho H; Herzka T; Watrud K; DeMarco DV; Wang VM; Senturk S; Fellmann C; Ding D; Beinortas T; Kleinman D; Chen M; Sordella R; Wilkinson JE; Castillo-Martin M; Cordon-Cardo C; Robinson BD; Trotman LC
Cancer Discov; 2015 Jun; 5(6):636-51. PubMed ID: 25829425
[TBL] [Abstract][Full Text] [Related]
8. CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.
Augello MA; Liu D; Deonarine LD; Robinson BD; Huang D; Stelloo S; Blattner M; Doane AS; Wong EWP; Chen Y; Rubin MA; Beltran H; Elemento O; Bergman AM; Zwart W; Sboner A; Dephoure N; Barbieri CE
Cancer Cell; 2019 Apr; 35(4):603-617.e8. PubMed ID: 30930119
[TBL] [Abstract][Full Text] [Related]
9. Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression?
Hlobilkova A; Ehrmann J; Sedlakova E; Krejci V; Knizetova P; Fiuraskova M; Kala M; Kalita O; Kolar Z
Neoplasma; 2007; 54(4):334-41. PubMed ID: 17822324
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.
De Velasco MA; Kura Y; Yoshikawa K; Nishio K; Davies BR; Uemura H
Oncotarget; 2016 Mar; 7(13):15959-76. PubMed ID: 26910118
[TBL] [Abstract][Full Text] [Related]
11. CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair.
Shenoy TR; Boysen G; Wang MY; Xu QZ; Guo W; Koh FM; Wang C; Zhang LZ; Wang Y; Gil V; Aziz S; Christova R; Rodrigues DN; Crespo M; Rescigno P; Tunariu N; Riisnaes R; Zafeiriou Z; Flohr P; Yuan W; Knight E; Swain A; Ramalho-Santos M; Xu DY; de Bono J; Wu H
Ann Oncol; 2017 Jul; 28(7):1495-1507. PubMed ID: 28383660
[TBL] [Abstract][Full Text] [Related]
12. CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage.
Zhu Y; Wen J; Huang G; Mittlesteadt J; Wen X; Lu X
Prostate; 2021 Jan; 81(1):81-88. PubMed ID: 33022763
[TBL] [Abstract][Full Text] [Related]
13. Hexokinase 2-mediated Warburg effect is required for PTEN- and p53-deficiency-driven prostate cancer growth.
Wang L; Xiong H; Wu F; Zhang Y; Wang J; Zhao L; Guo X; Chang LJ; Zhang Y; You MJ; Koochekpour S; Saleem M; Huang H; Lu J; Deng Y
Cell Rep; 2014 Sep; 8(5):1461-74. PubMed ID: 25176644
[TBL] [Abstract][Full Text] [Related]
14. PTEN, more than the AKT pathway.
Blanco-Aparicio C; Renner O; Leal JF; Carnero A
Carcinogenesis; 2007 Jul; 28(7):1379-86. PubMed ID: 17341655
[TBL] [Abstract][Full Text] [Related]
15. Characterizing the contribution of stem/progenitor cells to tumorigenesis in the Pten-/-TP53-/- prostate cancer model.
Abou-Kheir WG; Hynes PG; Martin PL; Pierce R; Kelly K
Stem Cells; 2010 Dec; 28(12):2129-40. PubMed ID: 20936707
[TBL] [Abstract][Full Text] [Related]
16. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
Tan M; Xu J; Siddiqui J; Feng F; Sun Y
Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654
[TBL] [Abstract][Full Text] [Related]
17. Methylseleninic Acid Superactivates p53-Senescence Cancer Progression Barrier in Prostate Lesions of Pten-Knockout Mouse.
Wang L; Guo X; Wang J; Jiang C; Bosland MC; Lü J; Deng Y
Cancer Prev Res (Phila); 2016 Jan; 9(1):35-42. PubMed ID: 26511486
[TBL] [Abstract][Full Text] [Related]
18. A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53.
Kim J; Roh M; Doubinskaia I; Algarroba GN; Eltoum IE; Abdulkadir SA
Oncogene; 2012 Jan; 31(3):322-32. PubMed ID: 21685943
[TBL] [Abstract][Full Text] [Related]
19. Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model.
Ai J; Pascal LE; O'Malley KJ; Dar JA; Isharwal S; Qiao Z; Ren B; Rigatti LH; Dhir R; Xiao W; Nelson JB; Wang Z
Oncogene; 2014 May; 33(18):2286-94. PubMed ID: 23708662
[TBL] [Abstract][Full Text] [Related]
20. PI3K/AKT pathway activation in bladder carcinogenesis.
Calderaro J; Rebouissou S; de Koning L; Masmoudi A; Hérault A; Dubois T; Maille P; Soyeux P; Sibony M; de la Taille A; Vordos D; Lebret T; Radvanyi F; Allory Y
Int J Cancer; 2014 Apr; 134(8):1776-84. PubMed ID: 24122582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]